| Year |
Citation |
Score |
| 2023 |
Keenlyside A, Marples T, Gao Z, Hu H, Nicely LG, Nogales J, Li H, Landgraf L, Solth A, Melzer A, Hossain-Ibrahim K, Huang Z, Banerjee S, Joseph J. Development and optimisation of in vitro sonodynamic therapy for glioblastoma. Scientific Reports. 13: 20215. PMID 37980454 DOI: 10.1038/s41598-023-47562-2 |
0.727 |
|
| 2023 |
Nicely LG, Baxter M, Banerjee S, Lord H. Sacral ependymoma presents 20 years after initial posterior fossa lesion. Bmj Case Reports. 16. PMID 37857539 DOI: 10.1136/bcr-2023-256611 |
0.726 |
|
| 2023 |
Tandon V, Moreno R, Allmeroth K, Quinn J, Wiley SE, Nicely LG, Denzel MS, Edwards J, de la Vega L, Banerjee S. Dual inhibition of HSF1 and DYRK2 impedes cancer progression. Bioscience Reports. PMID 36622366 DOI: 10.1042/BSR20222102 |
0.742 |
|
| 2022 |
Vala RM, Tandon V, Nicely LG, Guo L, Gu Y, Banerjee S, Patel HM. Synthesis of -(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBβ/AKT2 inhibitory and anti-glioma activity. Annals of Medicine. 54: 2549-2561. PMID 36120909 DOI: 10.1080/07853890.2022.2123559 |
0.738 |
|
| 2022 |
Nicely LG, Vala RM, Upadhyay DB, Nogales J, Chi C, Banerjee S, Patel HM. One-pot two-step catalytic synthesis of 6-amino-2-pyridone-3,5-dicarbonitriles enabling anti-cancer bioactivity. Rsc Advances. 12: 23889-23897. PMID 36093229 DOI: 10.1039/d2ra03579k |
0.755 |
|
| 2022 |
Ashraf M, Ismahel H, Lub S, Middleton E, Chaudhary A, Gardee A, Salloum LA, Szilagyi-Nagy E, Wales R, Omar S, Baird TA, O'Kane R, Holden J, Abdelsadg M, Burr P, ... ... Banerjee S, et al. Glasgow Neuro Society 2021 Conference Proceedings. Surgical Neurology International. 13: 173. PMID 35509535 DOI: 10.25259/SNI_268_2022 |
0.663 |
|
| 2022 |
Tandon V, Vala RM, Chen A, Sah RL, Patel HM, Pirrung MC, Banerjee S. Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo. Bioscience Reports. 42. PMID 35088066 DOI: 10.1042/BSR20212721 |
0.796 |
|
| 2021 |
Worby CA, Mayfield JE, Pollak AJ, Dixon JE, Banerjee S. The ABCs of the atypical Fam20 secretory pathway kinases. The Journal of Biological Chemistry. 296: 100267. PMID 33759783 DOI: 10.1016/j.jbc.2021.100267 |
0.55 |
|
| 2021 |
Van AN, Kunkel MT, Baffi TR, Lordén G, Antal CE, Banerjee S, Newton AC. Protein kinase C fusion proteins are paradoxically loss-of-function in cancer. The Journal of Biological Chemistry. 100445. PMID 33617877 DOI: 10.1016/j.jbc.2021.100445 |
0.37 |
|
| 2020 |
Tandon V, de la Vega L, Banerjee S. Emerging roles of DYRK2 in cancer. The Journal of Biological Chemistry. PMID 33376136 DOI: 10.1074/jbc.REV120.015217 |
0.796 |
|
| 2020 |
Moreno R, Banerjee S, Jackson AW, Quinn J, Baillie G, Dixon JE, Dinkova-Kostova AT, Edwards J, de la Vega L. The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress. Cell Death and Differentiation. PMID 33268814 DOI: 10.1038/s41418-020-00686-8 |
0.613 |
|
| 2019 |
Banerjee S, Wei T, Wang J, Lee JJ, Gutierrez HL, Chapman O, Wiley SE, Mayfield JE, Tandon V, Juarez EF, Chavez L, Liang R, Sah RL, Costello C, Mesirov JP, et al. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression. Proceedings of the National Academy of Sciences of the United States of America. PMID 31754034 DOI: 10.1073/Pnas.1912033116 |
0.78 |
|
| 2019 |
Edwards J, Baillie G, Quinn J, Monreno R, Banerjee S, Tomkinson N, MacKay S, Vega LDL. Abstract P3-10-10: DYRK2 is a novel therapeutic target in ER negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-10-10 |
0.523 |
|
| 2018 |
Qiu Y, Poppleton E, Mekkat A, Yu H, Banerjee S, Wiley SE, Dixon JE, Kaplan DL, Lin YS, Brodsky B. Enzymatic Phosphorylation of Ser in a Type I Collagen Peptide. Biophysical Journal. PMID 30527445 DOI: 10.1016/J.Bpj.2018.11.012 |
0.517 |
|
| 2018 |
Banerjee S, Ji C, Mayfield JE, Goel A, Xiao J, Dixon JE, Guo X. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2. Proceedings of the National Academy of Sciences of the United States of America. PMID 29987021 DOI: 10.1073/Pnas.1806797115 |
0.784 |
|
| 2017 |
Todoric J, Antonucci L, Di Caro G, Li N, Wu X, Lytle NK, Dhar D, Banerjee S, Fagman JB, Browne CD, Umemura A, Valasek MA, Kessler H, Tarin D, Goggins M, et al. Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell. PMID 29153842 DOI: 10.1016/J.Ccell.2017.10.011 |
0.337 |
|
| 2015 |
Guo X, Wang X, Wang Z, Banerjee S, Yang J, Huang L, Dixon JE. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis. Nature Cell Biology. PMID 26655835 DOI: 10.1038/Ncb3289 |
0.696 |
|
| 2015 |
Cozza G, Salvi M, Banerjee S, Tibaldi E, Tagliabracci VS, Dixon JE, Pinna LA. A new role for sphingosine: Up-regulation of Fam20C, the genuine casein kinase that phosphorylates secreted proteins. Biochimica Et Biophysica Acta. PMID 25936777 DOI: 10.1016/J.Bbapap.2015.04.023 |
0.753 |
|
| 2014 |
Banerjee S, Zagórska A, Deak M, Campbell DG, Prescott AR, Alessi DR. Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1βMYPT1 phosphatase complex and the SCFβTrCP E3 ubiquitin ligase. The Biochemical Journal. 461: 233-45. PMID 24785407 DOI: 10.1042/Bj20140408 |
0.72 |
|
| 2014 |
Banerjee S, Buhrlage SJ, Huang HT, Deng X, Zhou W, Wang J, Traynor R, Prescott AR, Alessi DR, Gray NS. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. The Biochemical Journal. 457: 215-25. PMID 24171924 DOI: 10.1042/Bj20131152 |
0.77 |
|
| 2010 |
Zagórska A, Deak M, Campbell DG, Banerjee S, Hirano M, Aizawa S, Prescott AR, Alessi DR. New roles for the LKB1-NUAK pathway in controlling myosin phosphatase complexes and cell adhesion. Science Signaling. 3: ra25. PMID 20354225 DOI: 10.1126/Scisignal.2000616 |
0.713 |
|
| Show low-probability matches. |